Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAd3-hliNSmut
- Development stage
- Phase 1
- Lead developer
- ReiThera
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ChAd3-hliNSmut is a prophylactic vaccine candidate developed for the prevention of hepatitis C virus (HCV) infection. It utilizes a chimpanzee adenovirus serotype 3 (ChAd3) vector encoding a mutated form of the HCV nonstructural proteins, with an invariant chain adjuvant to enhance immunogenicity. The vaccine is designed to stimulate robust CD4+ and CD8+ T cell responses against HCV antigens, aiming to provide protective immunity by boosting cellular immune responses. The primary indication for ChAd3-hliNSmut is chronic hepatitis C infection, and it has been studied in combination with MVA-hliNSmut as part of prime-boost vaccination regimens in early-phase clinical trials. The vaccine was initially developed at Oxford University and ReiThera Srl, with further development by GlaxoSmithKline[1][6][7][8].
02
Targets
γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on ChAd3-hliNSmut.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAd3-hliNSmut.